Ucb SA
XBRU:UCB

Watchlist Manager
Ucb SA Logo
Ucb SA
XBRU:UCB
Watchlist
Price: 178 EUR -2.57% Market Closed
Market Cap: 33.8B EUR
Have any thoughts about
Ucb SA?
Write Note

P/E
Price to Earnings

140.7
Current
37
Median
23
Industry
Higher than median
Higher than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
140.7
=
Market Cap
33.8B EUR
/
Net Income
240m EUR
All Countries
Close
Earnings Growth
BE
Ucb SA
XBRU:UCB
Average P/E: 46.6
140.7
399%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
89.2
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
24.9
-22%
US
Merck & Co Inc
NYSE:MRK
20.5
7 336%
CH
Roche Holding AG
SIX:ROG
18.1
32%
CH
Novartis AG
SIX:NOVN
12.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.4
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
41.6
2-Years Forward
P/E
26.2
3-Years Forward
P/E
19.7

See Also

Discover More